Skip to main content

Advertisement

Log in

Transverse Myelitis in Patients with Antiphospholipid Antibodies – The Importance of Early Diagnosis and Treatment

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract:

Transverse myelitis (TM) is a rare manifestation of systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). No uniform therapeutic protocol exists for its treatment, and the prognosis is usually poor. Here we describe four patients having TM associated with antiphospholipid antibodies. Treatment measures and delay in diagnosis between symptom onset and the initiation of treatment varied between patients, but the earlier the diagnosis and the more aggressive the treatment the better was the patient’s outcome. Based on these cases and on a literature review we suggest that early aggressive treatment (usually with pulses of methylprednisolone and cyclophosphamide) might improve the prognosis of patients with TM associated with antiphospholipid antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 13 March 2001 / Accepted: 3 October 2001

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sherer, Y., Hassin, S., Shoenfeld, Y. et al. Transverse Myelitis in Patients with Antiphospholipid Antibodies – The Importance of Early Diagnosis and Treatment. Clin Rheumatol 21, 207–210 (2002). https://doi.org/10.1007/s10067-002-8287-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-002-8287-2

Navigation